Prime Medicine, Inc. (PRME) Stock
Prime Medicine stock price chart
PRME stock quote & key statistics
Prime Medicine annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $4.6M | -$201.1M | -$1.37 |
| FY2024 | $3.0M | -$195.9M | -$1.65 |
| FY2023 | $0 | -$198.1M | -$2.18 |
| FY2022 | $5.2M | -$121.8M | -$2.73 |
| FY2021 | $0 | -$165.4M | — |
Fiscal year ending December 31. Source: company filings via EODHD.
About Prime Medicine, Inc.
Prime Medicine, Inc., a pioneering biotechnology firm, specializes in the development and application of genetic therapies aimed at treating various diseases through advanced gene editing technologies. At the forefront of their innovation are Prime Editors, distinguished by their unique composition of a Cas protein fused with a reverse transcriptase enzyme. This groundbreaking technology is complemented by pegRNA, which guides the Prime Editor to precise locations within the genome, facilitating targeted modifications to DNA sequences.
Founded in 2019, Prime Medicine, Inc. operates from its headquarters in Cambridge, Massachusetts, strategically positioning itself within a thriving biotech hub renowned for cutting-edge research and development. The company's mission is centered around harnessing the potential of genetic medicine to revolutionize healthcare, offering promising solutions to address unmet medical needs. Prime Medicine is committed to advancing the boundaries of genetic therapies, with a dedicated team of scientists and researchers driving innovation and translating groundbreaking discoveries into transformative treatments.
Central to Prime Medicine's approach is a commitment to rigorous scientific research and collaboration with leading experts in molecular biology and gene therapy. By leveraging deep expertise in genome editing, the company aims to deliver therapeutic solutions that not only correct genetic mutations but also pave the way for personalized medicine. Through strategic partnerships and a robust pipeline of innovative therapies, Prime Medicine continues to push the envelope in genetic medicine, aiming to improve patient outcomes and redefine the future of healthcare.
As Prime Medicine, Inc. continues to grow, it remains steadfast in its mission to harness the power of genetic editing technologies for the benefit of patients worldwide. With a focus on precision, innovation, and ethical standards, the company is poised to make significant strides in the field of biotechnology, offering hope for individuals affected by a wide range of genetic disorders and chronic diseases.
Prime Medicine stock FAQ
What is the Prime Medicine stock ticker symbol?
Prime Medicine, Inc. trades on the NASDAQ under the ticker symbol PRME.
What sector and industry is Prime Medicine in?
Prime Medicine, Inc. is classified in the Healthcare sector, Biotechnology industry.
How many employees does Prime Medicine have?
Prime Medicine, Inc. has about 146 full-time employees.
What were Prime Medicine's revenue and earnings last fiscal year?
Prime Medicine reported revenue of $4.6M and net income of -$201.1M in fiscal 2025, with earnings per share of -$1.37. Revenue grew 55.3% from the prior year.
Is Prime Medicine in the Russell 2000?
Yes. Prime Medicine, Inc. (PRME) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.
When did Prime Medicine go public?
Prime Medicine stock began trading on October 20, 2022.
Russell 2000 Biotechnology stocks
All Russell 2000 →- CGONCG Oncology
- COGTCogent Biosciences
- CRSPCRISPR Therapeutics
- CYTKCytokinetics
- DFTXDefinium Therapeutics
- DNTHDianthus Therapeutics
- IBRXImmunityBio
- IOVAIovance Biotherapeutics
- KODKodiak Sciences
- KRYSKrystal Biotech
- KYMRKymera Therapeutics
- LGNDLigand Pharmaceuticals
- MIRMMirum Pharmaceuticals
- ORKAOruka Therapeutics
- PCVXVaxcyte
- PRAXPraxis Precision Medicines
- PTCTPTC Therapeutics
- PTGXProtagonist Therapeutics
- RYTMRhythm Pharmaceuticals
- SRRKScholar Rock
- SYRESpyre Therapeutics
- TGTXTG Therapeutics
- TVTXTravere Therapeutics
- TWSTTwist Bioscience